Hutchison China MediTech Limited (NASDAQ:HCM) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday.

Separately, Canaccord Genuity upped their target price on Hutchison China MediTech Limited to $38.00 and gave the company a “buy” rating in a report on Monday, October 16th.

Shares of Hutchison China MediTech Limited (HCM) traded up 1.31% during midday trading on Thursday, reaching $27.77. 20,026 shares of the company’s stock traded hands. Hutchison China MediTech Limited has a 52 week low of $11.40 and a 52 week high of $32.03. The stock’s 50 day moving average is $27.75 and its 200-day moving average is $27.75. The company has a market capitalization of $3.37 billion, a PE ratio of 261.98 and a beta of -1.89.

ILLEGAL ACTIVITY NOTICE: “Hutchison China MediTech Limited (HCM) Cut to “Buy” at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/22/hutchison-china-meditech-limited-hcm-cut-to-buy-at-bidaskclub.html.

Several institutional investors and hedge funds have recently bought and sold shares of HCM. Wellington Management Group LLP boosted its stake in shares of Hutchison China MediTech Limited by 7.4% during the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock valued at $10,190,000 after acquiring an additional 35,053 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Hutchison China MediTech Limited during the first quarter valued at $618,000. JPMorgan Chase & Co. acquired a new stake in shares of Hutchison China MediTech Limited during the second quarter valued at $5,102,000. Baillie Gifford & Co. boosted its stake in shares of Hutchison China MediTech Limited by 6.1% during the second quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock valued at $3,905,000 after acquiring an additional 9,655 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Hutchison China MediTech Limited by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock valued at $2,420,000 after acquiring an additional 7,400 shares during the last quarter. 4.06% of the stock is currently owned by institutional investors and hedge funds.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.